Rigel Pharmaceuticals
RIGL
193 hedge funds and large institutions have $691M invested in Rigel Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 67 increasing their positions, 62 reducing their positions, and 26 closing their positions.
320% more call options, than puts
Call options by funds: $7.71M | Put options by funds: $1.84M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
96% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 26
62% more capital invested
Capital invested by funds: $426M → $691M (+$265M)
14% more funds holding
Funds holding: 169 → 193 (+24)
5.17% more ownership
Funds ownership: 83.75% → 88.92% (+5.2%)
8% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.2M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$16.3M |
| 3 |
Millennium Management
New York
|
+$12.3M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$9.59M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$8.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLGM
Capitolis Liquid Global Markets
New York
|
-$16.8M |
| 2 |
Janus Henderson Group
London,
|
-$7.33M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.24M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$4.54M |
| 5 |
Squarepoint
New York
|
-$4.49M |
RIGL Hedge Fund Activity: Q4 2025 in Review
193 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2025, worth a combined $691M — up 62% from $426M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new RIGL positions and 26 closed out — a net gain of 25 holders — while 67 added to existing stakes and 62 trimmed.
The largest buyer was State Street, adding an estimated $20.2M. The largest seller was Capitolis Liquid Global Markets, exiting entirely with an estimated $16.8M sold.
- 193 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2025, up from 169 in Q3 2025.
- Funds reported $691M of Rigel Pharmaceuticals stock for Q4 2025, up 62% quarter-over-quarter.
- 51 funds opened new Rigel Pharmaceuticals positions in Q4 2025 and 26 closed out, a net change of +25 holders.
- The largest Rigel Pharmaceuticals buyer in Q4 2025 was State Street, an estimated $20.2M added.
- The largest Rigel Pharmaceuticals seller in Q4 2025 was Capitolis Liquid Global Markets, an estimated $16.8M sold.
Based on aggregated 13F filings for Q4 2025.